HC Wainwright Reaffirms Buy Rating for Cognition Therapeutics (NASDAQ:CGTX)

Cognition Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright reiterated its Buy rating on Cognition Therapeutics and maintained a $3 price target, implying 400% upside from the stock’s then-current price.
  • Analyst views are mixed: three analysts rate CGTX a Buy and one a Sell, resulting in a MarketBeat consensus of Moderate Buy and an average target price of $3.33.
  • Cognition reported a quarterly loss of $0.04 per share, beating the consensus estimate of a $0.07 loss by $0.03.
  • MarketBeat previews top five stocks to own in December.

Cognition Therapeutics (NASDAQ:CGTX - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $3.00 price objective on the stock. HC Wainwright's target price would indicate a potential upside of 400.00% from the company's current price.

A number of other analysts have also recently commented on CGTX. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cognition Therapeutics in a research report on Monday, September 21st. Wall Street Zen downgraded shares of Cognition Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Cognition Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $3.33.

Check Out Our Latest Report on CGTX

Cognition Therapeutics Stock Performance

Shares of NASDAQ:CGTX opened at $0.60 on Thursday. The business's fifty day moving average price is $0.82 and its two-hundred day moving average price is $1.02. The stock has a market cap of $57.06 million, a PE ratio of -4.00 and a beta of 1.84. Cognition Therapeutics has a one year low of $0.55 and a one year high of $1.81.

Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.03. As a group, equities research analysts predict that Cognition Therapeutics will post -0.22 earnings per share for the current fiscal year.

Institutional Trading of Cognition Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Marshall Wace LLP purchased a new stake in Cognition Therapeutics in the 3rd quarter valued at about $68,000. Lido Advisors LLC purchased a new position in shares of Cognition Therapeutics during the 3rd quarter worth about $44,000. StoneX Group Inc. purchased a new position in shares of Cognition Therapeutics during the 3rd quarter worth about $30,000. Sigma Planning Corp lifted its holdings in shares of Cognition Therapeutics by 7.3% during the 2nd quarter. Sigma Planning Corp now owns 362,265 shares of the company's stock worth $417,000 after acquiring an additional 24,500 shares during the period. Finally, Corient Private Wealth LP acquired a new stake in shares of Cognition Therapeutics in the second quarter worth approximately $93,000. 43.35% of the stock is owned by hedge funds and other institutional investors.

About Cognition Therapeutics

(Get Free Report)

Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule treatments for neurodegenerative diseases and other disorders affecting the central nervous system and retina. The company's lead drug candidate, CT1812 (zervimesine), is an oral small molecule designed to target the sigma-2 receptor complex and disrupt the effects of toxic amyloid-beta oligomers on brain cells. Cognition has studied CT1812 in clinical programs for Alzheimer's disease and dementia with Lewy bodies, and has also investigated its potential in retinal disease.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cognition Therapeutics Right Now?

Before you consider Cognition Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cognition Therapeutics wasn't on the list.

While Cognition Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines